Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Structure/function claims proposal comment deadline extended to Sept. 25.

This article was originally published in The Tan Sheet

Executive Summary

STRUCTURE/FUNCTION PROPOSAL COMMENT DEADLINE EXTENDED UNTIL SEPT. 25 in response to a joint request from the National Nutritional Foods Association, the American Herbal Products Association and the Utah Natural Products Alliance, NNFA announced Aug. 11. An extension of the Aug. 27 deadline was supported by Sens. Orrin Hatch (R-Utah) and Tom Harkin (D-Iowa) in an Aug. 8 letter to FDA. "We are writing to urge that you give serious consideration to granting an extension of 30 days or more" to the Aug. 27 deadline for comments on the proposed rule, "the letter states. FDA's proposal to define the scope of structure/function claims for dietary supplements was published April 29 ("The Tan Sheet" May 4, pp. 1-5).

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel